These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32425947)

  • 1. Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions.
    Krieger E; Toor AA
    Front Immunol; 2020; 11():777. PubMed ID: 32425947
    [No Abstract]   [Full Text] [Related]  

  • 2. Natural regulation of immunity to minor histocompatibility antigens.
    Robertson NJ; Chai JG; Millrain M; Scott D; Hashim F; Manktelow E; Lemonnier F; Simpson E; Dyson J
    J Immunol; 2007 Mar; 178(6):3558-65. PubMed ID: 17339452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.
    Warren EH; Deeg HJ
    Tissue Antigens; 2013 Apr; 81(4):183-93. PubMed ID: 23510414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing graft-versus-leukemia after transplant: the rise of anti-cancer vaccines.
    Brusic A; Wu CJ
    Front Biosci (Landmark Ed); 2012 Jan; 17(2):635-55. PubMed ID: 22201766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation.
    Molldrem J; Riddell S
    Cancer Treat Res; 2009; 144():187-208. PubMed ID: 19779869
    [No Abstract]   [Full Text] [Related]  

  • 6. Hematopoietic stem cell transplantation and cellular therapy.
    Kolb HJ
    HLA; 2017 May; 89(5):267-277. PubMed ID: 28371460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer vaccines and T cell therapy.
    Rezvani K; Brody JD; Kohrt HE; Logan AC; Advani R; Czerwinski DK; Weng WK; Negrin RS; Carlton V; Faham M; Levy R; Barrett J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1 Suppl):S97-S101. PubMed ID: 23041602
    [No Abstract]   [Full Text] [Related]  

  • 8. T-cell therapy of leukemia.
    Riddell SR; Murata M; Bryant S; Warren EH
    Cancer Control; 2002; 9(2):114-22. PubMed ID: 11965232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of killer cell immunoglobulin-like receptor genotypes on acute graft-vs-host disease after unrelated hematopoietic stem cell transplantation in Koreans.
    Kim SY; Choi HB; Yoon HY; Choi EJ; Cho B; Kim HK; Kim YJ; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Kim CC; Kim TG
    Tissue Antigens; 2007 Apr; 69 Suppl 1():114-7. PubMed ID: 17445182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.
    Falkenburg JH; Marijt WA; Heemskerk MH; Willemze R
    Curr Opin Hematol; 2002 Nov; 9(6):497-502. PubMed ID: 12394171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Present status and future prospects in reduced intensity stem cell transplantation].
    Takaue Y
    Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1421-7. PubMed ID: 16097602
    [No Abstract]   [Full Text] [Related]  

  • 12. Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells.
    Adachi Y; Sakai T; Terakura S; Shiina T; Suzuki S; Hamana H; Kishi H; Sasazuki T; Arase H; Hanajiri R; Goto T; Nishida T; Murata M; Kiyoi H
    Int J Hematol; 2022 Mar; 115(3):371-381. PubMed ID: 35037229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras.
    Ghosh A; Koestner W; Hapke M; Schlaphoff V; Länger F; Baumann R; Koenecke C; Cornberg M; Welte K; Blazar BR; Sauer MG
    Blood; 2009 Apr; 113(18):4440-8. PubMed ID: 19182207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
    Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
    Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
    Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH
    Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD7 CAR T-Cell Therapy and Allogeneic HSCT.
    Fuji S
    N Engl J Med; 2024 Jul; 391(1):92. PubMed ID: 38959485
    [No Abstract]   [Full Text] [Related]  

  • 19. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Graft-versus-leukemia as an allogeneic immune reaction].
    Shiobara S
    Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1351-5. PubMed ID: 16097591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.